Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 358

Results For "SPE"

5001 News Found

R&D key for the growth of nation: Dr. Mandaviya
Policy | June 28, 2022

R&D key for the growth of nation: Dr. Mandaviya

The Minister lauded and extended his gratitude to the scientists who developed the vaccine during pandemic.


50%+ patients delay cataract surgeries in India: Survey
Public Health | June 28, 2022

50%+ patients delay cataract surgeries in India: Survey

73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries


PHARMAP 2022 concludes with productive networking of pharma leaders
News | June 28, 2022

PHARMAP 2022 concludes with productive networking of pharma leaders

The Congress was held on June, 20-21, 2022 in Berlin, Germany


Pharma industry warming up towards adoption of digital technologies
Digitisation | June 27, 2022

Pharma industry warming up towards adoption of digital technologies

By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities


Aurobindo Pharma Foundation distributes 15 tri motor bikes to physically challenged persons at Jadcherla, Telangana
News | June 27, 2022

Aurobindo Pharma Foundation distributes 15 tri motor bikes to physically challenged persons at Jadcherla, Telangana

Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.


Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against omicron
News | June 27, 2022

Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against omicron

Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine


Novartis commits US$ 250 million to the fight against NTDs and malaria
Public Health | June 24, 2022

Novartis commits US$ 250 million to the fight against NTDs and malaria

This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.


Novartis receives EC approval for Tabrecta for the treatment of non-small cell lung cancer
Drug Approval | June 24, 2022

Novartis receives EC approval for Tabrecta for the treatment of non-small cell lung cancer

Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally


Silo Pharma expands license agreement and patent portfolio
News | June 24, 2022

Silo Pharma expands license agreement and patent portfolio

Silo enters into commercial evaluation license agreement for next generation liposomes


Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine
News | June 24, 2022

Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine

An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.